---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-003153"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:18:52.955487+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Celldex completes Phase 3 CSU enrollment 6 months early; raises $345M; Q1 net loss $78.7M

## Summary
- Phase 3 CSU (EMBARQ-CSU1/2) enrolled 1,939 patients, 6 months ahead of guidance; topline data expected Q4 2026, BLA in 2027.
- Raised $345M gross in April 2026 public offering; cash at March 31, 2026 was $451.5M, supplemented by ~$323.9M net proceeds.
- Q1 2026 net loss $78.7M ($1.18/share) vs $53.8M ($0.81) in Q1 2025; R&D expenses $73M, up from $52.6M.
- Phase 1 CDX-622 proof-of-mechanism study in asthma ongoing; Phase 2 PN data summer 2026, AD data late 2026.
- Revenue $0 in Q1 2026 (vs $0.7M); management expects cash to fund operations through 2028.

## SEC filing metadata
- accession: 0001171843-26-003153
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/0001171843-26-003153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/f8k_050726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-003153
- JSON: https://secwatch.observer/filing/0001171843-26-003153.json
- Plain text: https://secwatch.observer/filing/0001171843-26-003153.txt

## Source-grounded claims
- claim_id: 797845456e912ce7d79566a8906e34f6df298b21
  claim: Celldex Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
  evidence_excerpt: On May 7, 2026, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter of 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/0001171843-26-003153-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.